Understanding the immunoangiostatic CXC chemokine network

Maria Luisa Balestrieri, Antonio Balestrieri, Francesco Paolo Mancini, Claudio Napoli

Research output: Contribution to journalArticlepeer-review


Chemokines, originally discovered as mediators of directional migration of immune cells to sites of inflammation and injury, have a function beyond their role in leukocyte chemotaxis. Indeed, they participate in organ development, angiogenesis, tumourigenesis and, more importantly, in the immune response. The chemokine family characterized by four highly conserved cysteine amino acid residues, with two cysteine residues (C) and a non-cysteine amino acid (X) between them (CXC), is known for its ability to promote trafficking of various leukocytes and to regulate angiogenesis and vascular remodelling. Intriguingly, the presence or absence of a structural-functional domain constituted by glutamic acid-leucine-arginine motif that precedes the first cysteine amino acid residue accounts for their unique property to induce or inhibit angiogenesis (angiogenic or angiostatic activity). The ability of CXC chemokine receptor 3 to promote Th1-dependent immunity and, at the same time, inhibit angiogenesis (immunoangiostasis) is of critical importance for inducing tumour regression. Agents that are able to inhibit angiogenic activities or promote angiostatic activities of CXC chemokines are future targets for research on cancer treatment. Here, we review insights on CXC chemokines in the context of immunoangiostasis and vascular damage.

Original languageEnglish
Pages (from-to)250-256
Number of pages7
JournalCardiovascular Research
Issue number2
Publication statusPublished - May 2008


  • Chemokines
  • CXCR3
  • Immunoangiostasis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Understanding the immunoangiostatic CXC chemokine network'. Together they form a unique fingerprint.

Cite this